Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Reform Bill Includes Tax Credit For Dx, Drug-Delivery Investments

This article was originally published in The Gray Sheet

Executive Summary

Companies with 250 or fewer employees would be eligible for a 50% tax credit on 2009-2010 investments in certain diagnostics, drug-delivery devices and pharmaceuticals under a provision in the Senate's health care reform bill

You may also be interested in...



Diagnostics Firms Poised To Gain From Innovation Tax Credit Program

Diagnostics firms stand to benefit most among medical device companies from $1 billion in life sciences innovation tax credits approved earlier this year, according to AdvaMed

Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality

Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.

Topics

UsernamePublicRestriction

Register

MT028367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel